Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in IDEAYA Biosciences, Inc. or Beam Therapeutics Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how IDEAYA Biosciences, Inc. and Beam Therapeutics Inc. compare based on key financial metrics to determine which better meets your investment needs.

About IDEAYA Biosciences, Inc. and Beam Therapeutics Inc.

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Latest Biotechnology and IDEAYA Biosciences, Inc., Beam Therapeutics Inc. Stock News

As of July 30, 2026, IDEAYA Biosciences, Inc. had a $3.5 billion market capitalization, compared to the Biotechnology median of $251.9 million. IDEAYA Biosciences, Inc.’s stock is up 2.7% in 2026, up 0.3% in the previous five trading days and up 46.54% in the past year.

Currently, IDEAYA Biosciences, Inc. does not have a price-earnings ratio. IDEAYA Biosciences, Inc.’s trailing 12-month revenue is $225.3 million with a -62.2% net profit margin. As of July 30, 2026, IDEAYA Biosciences, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.287 per share for the current fiscal year. IDEAYA Biosciences, Inc. does not currently pay a dividend.

As of July 30, 2026, Beam Therapeutics Inc. had a $2.6 billion market cap, putting it in the 58th percentile of all stocks. Beam Therapeutics Inc.’s stock is down 7.9% in 2026, up 1.7% in the previous five trading days and up 32.92% in the past year.

Currently, Beam Therapeutics Inc. does not have a price-earnings ratio. Beam Therapeutics Inc.’s trailing 12-month revenue is $164.0 million with a -40.2% net profit margin. Year-over-year quarterly sales growth most recently was 322.7%. Analysts expect adjusted earnings to reach $-4.435 per share for the current fiscal year. Beam Therapeutics Inc. does not currently pay a dividend.

How We Compare IDEAYA Biosciences, Inc. and Beam Therapeutics Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at IDEAYA Biosciences, Inc. and Beam Therapeutics Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

IDEAYA Biosciences, Inc. and Beam Therapeutics Inc. Stock Value Grades

Company	Ticker	Value
IDEAYA Biosciences, Inc.	IDYA	F
Beam Therapeutics Inc.	BEAM	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

IDEAYA Biosciences, Inc. has a Value Score of 16, which is Ultra Expensive. Beam Therapeutics Inc. has a Value Score of 11, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither IDEAYA Biosciences, Inc. or Beam Therapeutics Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if IDEAYA Biosciences, Inc. or Beam Therapeutics Inc. is the better investment when it comes to value.

IDEAYA Biosciences, Inc. and Beam Therapeutics Inc. Growth Grades

Company	Ticker	Growth
IDEAYA Biosciences, Inc.	IDYA	F
Beam Therapeutics Inc.	BEAM	na

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

IDEAYA Biosciences, Inc. has a Growth Score of 12, which is Very Weak. Beam Therapeutics Inc. does not have a meaningful Growth Score.

The Growth Stock Winner: No Clear Winner

Neither IDEAYA Biosciences, Inc. or Beam Therapeutics Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if IDEAYA Biosciences, Inc. or Beam Therapeutics Inc. is the better investment when it comes to sustainable growth.

IDEAYA Biosciences, Inc. and Beam Therapeutics Inc.’s Momentum Grades

Company	Ticker	Momentum
IDEAYA Biosciences, Inc.	IDYA	B
Beam Therapeutics Inc.	BEAM	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

IDEAYA Biosciences, Inc. has a Momentum Score of 80, which is Strong. Beam Therapeutics Inc. has a Momentum Score of 52, which is Average.

The Momentum Grade Winner: IDEAYA Biosciences, Inc.

As you can clearly see from the Momentum Grade breakdown above, IDEAYA Biosciences, Inc. is considered to have stronger momentum compared to Beam Therapeutics Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, IDEAYA Biosciences, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other IDEAYA Biosciences, Inc. and Beam Therapeutics Inc. Grades

In addition to Momentum, Growth and Value, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether IDEAYA Biosciences, Inc. and Beam Therapeutics Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, IDEAYA Biosciences, Inc. or Beam Therapeutics Inc. Stock?

Overall, IDEAYA Biosciences, Inc. stock has a Value Score of 16, Growth Score of 12 and Momentum Score of 80.

Beam Therapeutics Inc. stock has a Value Score of 11, Growth Score of and Momentum Score of 52.

Comparing IDEAYA Biosciences, Inc. and Beam Therapeutics Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.